$63.7 Million is the total value of Summit Rock Advisors, LP's 4 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 60.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EWJ | New | ISHARES INCmsci jpn etf new | $35,390,000 | – | 698,174 | +100.0% | 55.55% | – |
IEMG | Sell | ISHARES INCcore msci emkt | $13,820,000 | -37.0% | 293,113 | -30.8% | 21.69% | -10.1% |
ACWI | Sell | ISHARES TRmsci acwi etf | $9,881,000 | -69.9% | 154,002 | -65.1% | 15.51% | -57.0% |
HYG | Sell | ISHARES TRiboxx hi yd etf | $4,620,000 | -67.8% | 56,972 | -65.7% | 7.25% | -54.1% |
EFV | Exit | ISHARES TReafe value etf | $0 | – | -190,295 | -100.0% | -10.87% | – |
IUSV | Exit | ISHARES TRcore s&p us vlu | $0 | – | -211,818 | -100.0% | -13.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-07
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ISHARES TR | 29 | Q3 2020 | 90.6% |
ISHARES TR | 26 | Q4 2020 | 51.7% |
ISHARES INC | 11 | Q1 2020 | 64.0% |
ISHARES TR | 11 | Q4 2021 | 47.6% |
ISHARES TR | 9 | Q2 2015 | 34.5% |
PHATHOM PHARMACEUTICALS INC | 9 | Q2 2022 | 1.1% |
ISHARES TR RUS 2000 VAL ETF | 7 | Q4 2022 | 47.0% |
SELECT SECTOR SPDR TR ENERGY | 6 | Q3 2023 | 67.4% |
VANGUARD INTL EQUITY INDEX F | 5 | Q3 2022 | 45.3% |
VANGUARD INDEX FDS | 4 | Q4 2021 | 36.4% |
View Summit Rock Advisors, LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-01-26 |
13F-HR | 2023-10-24 |
13F-HR | 2023-07-21 |
13F-HR | 2023-05-09 |
13F-HR | 2023-01-12 |
13F-HR | 2022-11-02 |
13F-HR | 2022-08-01 |
13F-HR | 2022-05-06 |
13F-HR | 2022-02-14 |
13F-HR | 2021-10-26 |
View Summit Rock Advisors, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.